Newsroom | 2108 results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc., a spatial multi-omics innovator accelerating biological discovery and new drug development, today announced that it will present new spatial multi-omics data at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting on November 7-10, 2025 in National Harbor, Maryland. The company will showcase how researchers can generate a combination of high-quality RNA and protein data via Vizgen’s bioinformatics technology. Vizgen combined results...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--GXP-Storage’s ISO 20387:2018 and 9001:2015 certifications creates a comprehensive dual ISO quality framework for regulated material management....

DOVER, Del.--(BUSINESS WIRE)--Identy.io announced it achieved NIST ISO 30107-3 Level 2 PAD Certification with a perfect score for its Face SDK v6.3.0 application....

INGELHEIM, Germany and ZURICH, Switzerland--(BUSINESS WIRE)--Boehringer Ingelheim and CDR-Life, Inc. today announced a new global licensing agreement to develop CDR-Life’s unique antibody-based molecule CDR111 for autoimmune diseases. CDR111 is a trispecific M-gager®, an antibody-based T-cell engager designed to selectively target and deplete B cells, with the goal of achieving immune system reset. Dysregulated B cells play a central role in driving many autoimmune and inflammatory conditions s...

BARCELONA, Spain--(BUSINESS WIRE)--REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company seeking to revolutionize precision oncology through biomarker innovation, today announced the publication of the study “HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy” in Nature Communications. This landmark study evaluated the HER2DX genomic assay in 154 individuals aged 70–80 years enrolled in the RESPECT tr...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $851 million for the third quarter ended September 30, 2025, compared to $709 million for the same period of 2024. “Exact Sciences continues to advance our mission to prevent cancer and detect it earlier through a relentless focus on patients,” said Kevin Conroy, chairman and CEO. “Our third quarter results reflec...

LONDON--(BUSINESS WIRE)--iProov, the world's leading provider of science-based biometric identity verification solutions, today announced that it is the first and only vendor to meet the biometric verification requirements included in the new NIST Special Publication 800-63-4 Digital Identity Guidelines. This achievement is independently established by the combination of recent testing of iProov Dynamic Liveness by an ISO-accredited lab to the new CEN18099 injection attack standard, together wi...

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the EZ2 DNA Investigator Sep&Prep Kit, a fully automated solution for processing sexual assault samples, at the upcoming International Symposium on Human Identification 2025 (ISHI) from November 3-6 in Palm Beach, Florida. Developed specifically for forensic laboratories, the EZ2 DNA Investigator Sep&Prep kit enhances the separation of sperm from n...

DUBLIN--(BUSINESS WIRE)--The "USA Pharmaceutical Directory 2025" directory has been added to ResearchAndMarkets.com's offering. The USA Pharmaceutical Directory is one of the most comprehensive and accurate directories of companies and executives in the USA pharmaceutical industry that have ever been published. It contains more than 4,000 pharmaceutical companies and 8,000 executives working in the industry. This powerful directory is your connection to key decision-makers in the pharmaceutical...

SAN MATEO, Calif.--(BUSINESS WIRE)--Curve Biosciences Raises $40 Million to Bring Whole-Body Intelligence to Chronic Disease Monitoring...